Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Agoura Hills, CA, US. The stock last traded at $0.03, down 0.29% on the session, giving a market capitalisation of $15.0M. On trailing twelve-month figures it carries a trailing P/E of 0.06, a net margin of 0.0%. Its beta of -0.23 implies it has historically moved less than the broad market.
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Oncotelic Therapeutics, Inc. is most often compared with the following Healthcare names: